SCHEDULE 13D
Item 1. Security and Issuer
This Schedule 13D relates to shares of common stock, par value $0.0001 per share (“Common Stock”), of Inhibitor Therapeutics, Inc., a Delaware corporation (the “Company”). The principal executive offices of the Company are located at 900 West Platt St, Suite 200, Tampa, FL 33606.
Item 2. Identity and Background
| (a) | This Schedule 13D is being filed by Black Robe Capital, LLC, which is the holder of record of approximately 11.7% of the issued and outstanding shares of Common Stock of the Company as of the date hereof (“Black Robe”) and James McNulty, the sole manager of Black Robe (collectively, with Black Robe, the “Reporting Persons”). |
| (b) | The principal business and principal office address of each of the Reporting Persons is 900 West Platt St, Suite 200, Tampa, FL 33606. |
| (c) | Present Principal Occupation or Employment |
For Black Robe: Not applicable
For Mr. McNulty: Chief Financial Officer of the Company and sole manager of Black Robe
| (d) | During the last five years, neither of the Reporting Person has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). |
| (e) | During the last five years, neither of the Reporting Persons was a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws, or finding any violation with respect to such laws. |
| (f) | Citizenship/Place of Organization |
For Black Robe:
For Mr. McNulty: United States of America
Item 3. Source and Amount of Funds or Other Consideration
Hedgepath, LLC, the holder of 79,627,069 shares of Common Stock of the Company, effected a pro rata distribution of its shares to its members. Each of the Reporting Persons were members of Hedgepath, LLC and received their respective pro rata portion of the distribution of the shares of Common Stock of the Company.
Item 4. Purpose of Transaction
The Reporting Persons have no current plans or proposals which relate to, or could result in, any of the matters referred to in paragraphs (a) through (j) of Item 4 of Schedule 13D.